S A Narod1, N Tung2, J Lubinski3, T Huzarski3, M Robson4, H T Lynch5, S L Neuhausen6, P Ghadirian7, C Kim-Sing8, P Sun1, W D Foulkes9. 1. Women's College Research Institute, University of Toronto, Toronto, ON. 2. Beth Israel Deaconness Hospital, Boston, MA, U.S.A. 3. Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland. 4. Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York City, NY, U.S.A. 5. Department of Preventive Medicine, Creighton University, Omaha, NE, U.S.A. 6. Beckman Research Institute of the City of Hope, Duarte, CA, U.S.A. 7. Epidemiology Research Unit, CHUM-Hôtel-Dieu, Montreal, QC. 8. BC Cancer Agency, Vancouver, BC. 9. Departments of Medical Genetics and Oncology, McGill University, Montreal, QC.
Abstract
BACKGROUND: The risk of breast cancer in carriers of BRCA1 and BRCA2 mutations is influenced by factors other than the genetic mutation itself. Modifying factors include a woman's reproductive history and family history of cancer. Risk factors are more likely to be present in women with breast cancer than in women without breast cancer, and therefore the risk of cancer in the two breasts should not be independent. It is not clear to what extent modifying factors influence the risk of a first primary or a contralateral breast cancer in BRCA carriers. METHODS: We conducted a matched case-control study of breast cancer among 3920 BRCA1 or BRCA2 mutation carriers. We asked whether a past history of breast cancer in the contralateral breast was a risk factor for breast cancer. RESULTS: After adjustment for age, country of residence, and cancer treatment, a previous cancer of the right breast was found to be a significant risk factor for cancer of the left breast among BRCA1 or BRCA2 carriers (relative risk: 2.1; 95% confidence interval: 1.4 to 3.0; p < 0.0001). CONCLUSIONS: In a woman with a BRCA1 or BRCA2 mutation who is diagnosed with breast cancer, the risk of cancer in the contralateral breast depends on the first diagnosis. That observation supports the hypothesis that there are important genetic or non-genetic modifiers of cancer risk in BRCA carriers. Discovering risk modifiers might lead to greater personalization of risk assessment and management recommendations for BRCA-positive patients.
BACKGROUND: The risk of breast cancer in carriers of BRCA1 and BRCA2 mutations is influenced by factors other than the genetic mutation itself. Modifying factors include a woman's reproductive history and family history of cancer. Risk factors are more likely to be present in women with breast cancer than in women without breast cancer, and therefore the risk of cancer in the two breasts should not be independent. It is not clear to what extent modifying factors influence the risk of a first primary or a contralateral breast cancer in BRCA carriers. METHODS: We conducted a matched case-control study of breast cancer among 3920 BRCA1 or BRCA2 mutation carriers. We asked whether a past history of breast cancer in the contralateral breast was a risk factor for breast cancer. RESULTS: After adjustment for age, country of residence, and cancer treatment, a previous cancer of the right breast was found to be a significant risk factor for cancer of the left breast among BRCA1 or BRCA2 carriers (relative risk: 2.1; 95% confidence interval: 1.4 to 3.0; p < 0.0001). CONCLUSIONS: In a woman with a BRCA1 or BRCA2 mutation who is diagnosed with breast cancer, the risk of cancer in the contralateral breast depends on the first diagnosis. That observation supports the hypothesis that there are important genetic or non-genetic modifiers of cancer risk in BRCA carriers. Discovering risk modifiers might lead to greater personalization of risk assessment and management recommendations for BRCA-positive patients.
Entities:
Keywords:
BRCA1; BRCA2; contralateral breast cancer
Authors: Jan Lubinski; Tomasz Huzarski; Tomasz Byrski; Henry T Lynch; Cezary Cybulski; Parviz Ghadirian; Malgorzata Stawicka; William D Foulkes; Ewa Kilar; Charmaine Kim-Sing; Susan L Neuhausen; Susan Armel; Dawna Gilchrist; Kevin Sweet; Jacek Gronwald; Andrea Eisen; Bohdan Gorski; Ping Sun; Steven A Narod Journal: Int J Cancer Date: 2011-09-22 Impact factor: 7.396
Authors: Kelly Metcalfe; Jan Lubinski; Henry T Lynch; Parviz Ghadirian; William D Foulkes; Charmaine Kim-Sing; Susan Neuhausen; Nadine Tung; Barry Rosen; Jacek Gronwald; Peter Ainsworth; Kevin Sweet; Andrea Eisen; Ping Sun; Steven A Narod Journal: J Natl Cancer Inst Date: 2010-11-23 Impact factor: 13.506
Authors: Joanne Kotsopoulos; Jan Lubinski; Henry T Lynch; Susan L Neuhausen; Parviz Ghadirian; Claudine Isaacs; Barbara Weber; Charmaine Kim-Sing; William D Foulkes; Ruth Gershoni-Baruch; Peter Ainsworth; Eitan Friedman; Mary Daly; Judy E Garber; Beth Karlan; Olufunmilayo I Olopade; Nadine Tung; Howard M Saal; Andrea Eisen; Michael Osborne; Hakan Olsson; Dawna Gilchrist; Ping Sun; Steven A Narod Journal: Cancer Causes Control Date: 2005-08 Impact factor: 2.506
Authors: Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton Journal: J Natl Cancer Inst Date: 2013-04-29 Impact factor: 13.506
Authors: Jeffrey N Weitzel; Mark Robson; Barbara Pasini; Siranoush Manoukian; Dominique Stoppa-Lyonnet; Henry T Lynch; Jane McLennan; William D Foulkes; Teresa Wagner; Nadine Tung; Parviz Ghadirian; Olufunmilayo Olopade; Claudine Isaacs; Charmaine Kim-Sing; Pal Møller; Susan L Neuhausen; Kelly Metcalfe; Ping Sun; Steven A Narod Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: H Jernström; J Lubinski; H T Lynch; P Ghadirian; S Neuhausen; C Isaacs; B L Weber; D Horsman; B Rosen; W D Foulkes; E Friedman; R Gershoni-Baruch; P Ainsworth; M Daly; J Garber; H Olsson; P Sun; S A Narod Journal: J Natl Cancer Inst Date: 2004-07-21 Impact factor: 13.506
Authors: Kelly Metcalfe; Shelley Gershman; Parviz Ghadirian; Henry T Lynch; Carrie Snyder; Nadine Tung; Charmaine Kim-Sing; Andrea Eisen; William D Foulkes; Barry Rosen; Ping Sun; Steven A Narod Journal: BMJ Date: 2014-02-11